The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe.
Open accessAbstract
Background & aims Moderate cure rates of acute hepatitis C virus (HCV) infections with pegylated interferon and ribavirin have been described in the last decade in men who have sex with men (MSM), who are also coinfected with the human immunodeficiency virus (HIV). However, a subsequent high incidence of HCV reinfections has been reported regionally in men who both clear the infection spontaneously or who respond to treatment.Methods Retrospective analysis of reinfections in HIV infected MSM in eight centers from Austria, France, Germany, and the UK within the NEAT network between May 2002 and June 2014.Results Of 606 individuals who cleared HCV spontaneously or were successfully treated, 149 (24.6%) presented with a subsequent HCV reinfection. Thirty out of 70 (43%) who cleared again or were successfully treated, presented with a second reinfection, 5 with a third, and one with a fourth reinfection. The reinfection incidence was 7.3/100 person-years (95% CI 6.2-8.6). We found a trend for lower incidence among individuals who had spontaneously cleared their incident infection than among individuals who were treated (Hazard ratio 0.62, 95% CI 0.38-1.02, p=0.06). Spontaneous clearance of reinfection was associated with ALT levels >1000IU/ml and spontaneous clearance of a prior infection.Conclusions HCV reinfection is an issue of major concern in HIV-positive MSM. Prevention strategies are needed for high risk groups to reduce morbidity and treatment costs. HIV-positive MSM with a prior HCV infection should be tested every 3 to 6months for reinfection. Those who had achieved a reinfection should be tested every 3months.Lay summary We evaluated the occurrence of HCV reinfection in HIV-positive men who have sex with men. We found an alarming incidence of 7.3/100 person-years. Prevention measures need to address this specific subgroup of patients at high risk for HCV.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Because acute HCV infection acquisition among persons with HIV infection can occur, especially among MSM, and regular screening of those with HIV is cost-effective (238,239,1377), periodic HCV screening should be conducted (1378–1380).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [1380]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Smith, C. J., Ryom, L., Weber, R. K., Morlat, P., Pradier, C., Reiss, P., Kowalska, J. D., Wit, S. D., Law, M. G., El‐Sadr, W., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60604-8 · Cited by 950
The Outcome of Acute Hepatitis C Predicted by the Evolution of the Viral Quasispecies
Farci, P., Shimoda, A., Coiana, A., Diaz, G., Peddis, G., Melpolder, J. C., Strazzera, A., Chien, D. Y., Muñoz, S. J., Balestrieri, A., et al. (2000) · Science · doi:10.1126/science.288.5464.339 · Cited by 882
Pestka, J. M., Zeisel, M. B., Bläser, E., Schürmann, P., Bartosch, B., Cosset, F., Patel, A. H., Meisel, H., Baumert, J. J., Viazov, S. O., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607026104 · Cited by 565
Martin, N. K., Vickerman, P. T., Grebely, J., Hellard, M. E., Hutchinson, S. J., Lima, V. D., Foster, G. R., Dillon, J. F., Goldberg, D. J., Dore, G. J., et al. (2013) · Hepatology · doi:10.1002/hep.26431 · Cited by 488
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1
Naggie, S., Cooper, C., Saag, M. S., Workowski, K., Ruane, P. J., Towner, W. J., Marks, K., Luetkemeyer, A. F., Baden, R. P., Sax, P. E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501315 · Cited by 467
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1
Wyles, D. L., Ruane, P. J., Sulkowski, M., Dieterich, D. T., Luetkemeyer, A. F., Morgan, T. R. M., Sherman, K. E., Dretler, R. H., Fishbein, D. A., Gathe, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503153 · Cited by 411
Danta, M., Brown, D., Bhagani, S., Pybus, O. G., Sabin, C. A., Nelson, M., Fisher, M., Johnson, A. M., & Dusheiko, G. M. (2007) · AIDS · doi:10.1097/qad.0b013e3281053a0c · Cited by 410
Self-citationOsburn, W. O., Fisher, B. E., Dowd, K. A., Urban, G., Liu, L., Ray, S. C., Thomas, D. L., & Cox, A. L. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.09.017 · Cited by 360
Bourne, A. H., Reid, D., Hickson, F. C. I., Rueda, S. T., & Weatherburn, P. (2015) · Sexually Transmitted Infections · doi:10.1136/sextrans-2015-052052 · Cited by 330
Tillmann, H. L., Thompson, A. J. V., Patel, K., Wiese, M., Tenckhoff, H., Nischalke, H. D., Lokhnygina, Y. V., Kullig, U., Göbel, U., Capka, E., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.07.005 · Cited by 321
Cited by
Sorted by citations
Items 101–170 of 170
Gaeta, G. B., Puoti, M., Coppola, N., Santantonio, T. A., Bruno, R., Chirianni, A., & Galli, M. (2017) · Infection · doi:10.1007/s15010-017-1107-z · Cited by 7
Liu, C., & Kao, J. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1499 · Cited by 7
Wyles, D. L., Kang, M., Matining, R. M., Murphy, R. L., Peters, M. G., & VHICS Study Team (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy103 · Cited by 6
Pisaturo, M., Minichini, C., Starace, M., Caroprese, M., Macera, M., Brancaccio, G., Pascalis, S. D., Santonicola, A., Lanza, A. G., Zampino, R., et al. (2018) · Liver International · doi:10.1111/liv.14025 · Cited by 6
Predictive factors of hepatitis C virus eradication after interferon-free therapy in HIV coinfection
Domínguez, L., Bisbal, O., Matarranz, M., Lagarde, M., Pinar, Ó., Hernando, A., Lumbreras, C., Rubio, R., & Pulido, F. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03488-0 · Cited by 6
Martin, N. K., Skaathun, B., Vickerman, P. T., & Stuart, D. (2017) · PubMed · Cited by 6
Popping, S., Cuypers, L., Claassen, M. A. A., van den Berk, G. E. L., Weggheleire, A. D., Arends, J. E., Boerekamps, A., Molenkamp, R., Koopmans, M., Verbon, A., et al. (2022) · Viruses · doi:10.3390/v14091953 · Cited by 5
Ma, J., Nance, R. M., Cachay, E. R., Ruderman, S. A., Kitahata, M. M., Falade-Nwulia, O. O., Chander, G., Drumright, L. N., Hurt, C. B., Yendewa, G. A., et al. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf030 · Cited by 5
Is Hepatitis C Virus Elimination in Well-Defined Patient Groups Possible?
Rockstroh, J. K. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix1010 · Cited by 5
Self-citationSepúlveda‐Crespo, D., Yélamos, B., Díez, C., Gómez, J., Hontañón, V., Torresano-Felipe, F., Berenguer, J., González‐García, J., Ibáñez, L., Llop, E., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113024 · Cited by 5
Chronic Hepatitis C Virus Infection: An Ongoing Challenge in Screening and Treatment
Tsai, W.-C., Chiang, H., Chiu, Y., Chien, S.-C., Cheng, P., & Chiu, H. (2023) · Life · doi:10.3390/life13101964 · Cited by 5
Crowell, T. A., Qian, H., Tiemann, C., Lehmann, C., Boesecke, C., Stoehr, A. D., Hartikainen, J., Eßer, S., Bickel, M., Spinner, C. D., et al. (2021) · AIDS Research and Therapy · doi:10.1186/s12981-021-00378-4 · Cited by 5
Self-citationHepatitis C virus reinfection—more to come?
Ingiliz, P., & Rockstroh, J. K. (2016) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(16)30223-0 · Cited by 5
Self-citationGirometti, N., Devitt, E. J., Phillips, J., Nelson, M. R., & Whitlock, G. G. (2019) · Journal of Viral Hepatitis · doi:10.1111/jvh.13066 · Cited by 5
Self-citationHuang, M., Chen, G., & Hung, C. (2025) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2025.08.039 · Cited by 4
Sacks‐Davis, R., Pedrana, A. E., Scott, N., Doyle, J., & Hellard, M. E. (2018) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2018.1471355 · Cited by 4
Pre-Exposure Prophylaxis for viral infections other than HIV
Soriano, V., Treviño, A., de Mendoza, C., Moreno‐Torres, V., Pintos-Pascual, I., Barreiro, P., & Corral, O. J. (2022) · Infezioni in Medicina · doi:10.53854/liim-3003-5 · Cited by 4
Viral Hepatitis C: From Unraveling the Nature of Disease to Cure and Global Elimination
Basytė-Bacevičė, V., & Kupčinskas, L. (2024) · Digestive Diseases · doi:10.1159/000539210 · Cited by 4
Vigón, L., Vázquez‐Morón, S., Berenguer, J., González‐García, J., Jiménez‐Sousa, M. Á., Guardiola, J. M., Casal, M. C., Santos, I. D. L., von Wichmann, M. Á., Carrero, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-48592-5 · Cited by 4
Millman, A. J., Luo, Q., Nelson, N. P., Vellozzi, C. J., & Weiser, J. K. (2019) · AIDS Care · doi:10.1080/09540121.2019.1668533 · Cited by 4
Marquez, L. K., Ingiliz, P., Boesecke, C., Krznaric, I., Schewe, K., Lutz, T., Mauss, S., Christensen, S., Rockstroh, J. K., Jain, S., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267853 · Cited by 4
Self-citationIngiliz, P. (2017) · Journal of Viral Hepatitis · doi:10.1111/jvh.12686 · Cited by 4
Self-citationTreatment of acute hepatitis C in HIV coinfection: Is this a chance for achieving microelimination?
Rockstroh, J. K., & Boesecke, C. (2019) · United European Gastroenterology Journal · doi:10.1177/2050640619843735 · Cited by 4
Self-citationHCV serology: an unfinished agenda
Galli, C., & Plebani, M. (2025) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2025-0501 · Cited by 3
Diagnosis and Clinical Manifestations of Acute Hepatitis C Infection in People Living with HIV
O’Shea, J., Oliver, N. T., & Cartwright, E. J. (2022) · AIDS Patient Care and STDs · doi:10.1089/apc.2022.0021 · Cited by 3
HIV/HCV Coinfection: Current Challenges
Salmon, D., Arends, J. E., Leoni, C., Solas, C., & Peytavin, G. (2019) · Springer eBooks · doi:10.1007/978-3-030-03757-4_7 · Cited by 3
Update on hepatitis C virus management
Peer, A. D., & Price, J. C. (2025) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001098 · Cited by 2
Interventions to reduce acute hepatitis C virus in HIV-positive MSM
Elliott, T., Cooke, G., & Garvey, L. J. (2019) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000614 · Cited by 2
CROI 2018: Highlights of Viral Hepatitis.
Luetkemeyer, A. F., & Wyles, D. L. (2018) · Europe PMC (PubMed Central) · Cited by 2
Management of Hepatitis C–Infected Patients After Sustained Virological Response
Pearlman, B. L. (2020) · Clinical Liver Disease · doi:10.1002/cld.913 · Cited by 2
Wyles, D. L., Kang, M., Matining, R. M., Murphy, R. L., & Peters, M. G. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab511 · Cited by 2
COVID-19: Way Forward With Serosurveillance Without Overemphasizing Neutralizing Antibodies
Kršák, M., Henao‐Martínez, A. F., & Franco‐Paredes, C. (2020) · Viral Immunology · doi:10.1089/vim.2020.0246 · Cited by 2
Bhagani, S. R. (2018) · Liver International · doi:10.1111/liv.13937 · Cited by 2
Self-citationRockstroh, J. K. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1113 · Cited by 2
Self-citationNguyen, T., Valantin, M., Delaugerre, C., Amiel, C., Netzer, E., L’Yavanc, T., Ohayon, M., Valin, N., Day, N., Kreplak, G., et al. (2021) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2021.01.012 · Cited by 1
Effectiveness of hepatitis C antiviral treatment and feasibility of hepatitis C elimination goal
Burgui, C., Miguel, R. S., Esarte, S. G., Juanbeltz, R., Úriz-Otano, J. I., Repáraz, J., Carricas, M. S., Zozaya, J. M., & Castilla, J. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2141499 · Cited by 1
Are reinfections undermining HCV elimination efforts?
Chromy, D., & Mandorfer, M. (2024) · The Lancet HIV · doi:10.1016/s2352-3018(23)00309-0 · Cited by 1
Self-citationTsai, T., Chen, G., Sun, H., & Hung, C. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf576 · Cited by 1
Low incidence of acute hepatitis C virus infection among Southern Spanish HIV-infected individuals
Mancebo, M., Macı́as, J., Merchante, N., Real, L. M., Lozano, F., Domínguez, L., Álvarez-Ossorio, M. J., Saussol, F., Rincón, P., Pineda, J. A., et al. (2017) · Journal of Infection · doi:10.1016/j.jinf.2017.01.013 · Cited by 1
Dennin, R. H. (2017) · World Journal of AIDS · doi:10.4236/wja.2017.72012 · Cited by 1
Laguno, M., Martínez‐Rebollar, M., de la Mora, L., Pérez‐del‐Pulgar, S., & Mallolas, J. (2019) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2019.04.005 · Cited by 1
Pozza, R., McCoy-Hill, C., Hall, K., Hefner, A. M., Wilgers, K., Tapelband, J. E., Masroor, M., & Hassanein, T. (2019) · The Nurse Practitioner · doi:10.1097/01.npr.0000586008.23422.2c · Cited by 1
Duracinský, M., Dimi, S., Carrieri, P., Yaya, I., Timsit, J., Farfour, É., Fouéré, S., Chassany, O., & Zucman, D. (2022) · Research Square · doi:10.21203/rs.3.rs-1652077/v1 · Cited by 1
Klären Sie über HCV-Reinfektionen auf
Grzegorek, K. (2018) · CME · doi:10.1007/s11298-018-6664-7
Arends, J. E., Leoni, M. C., & Salmon, D. (2019) · Springer eBooks · doi:10.1007/978-3-030-03535-8_4
Hepatitis C reinfection with protease inhibitor‐resistant hepatitis C virus in an HIV‐coinfected MSM
YILMAZ, G. R., Boesecke, C., Schwarze‐Zander, C., & Rockstroh, J. K. (2019) · Liver International · doi:10.1111/liv.14275
Self-citationOpioid use disorder and rural America
Akhtar, W. Z., & Feinberg, J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-68328-9.00003-5
Epidemiology of Hepatitis C Virus: People Who Inject Drugs and Other Key Populations
Wiessing, L. G., Giraudon, I., Duffell, E. F., Veldhuijzen, I. K., Zimmermann, R., & Hope, V. D. (2021) · Springer eBooks · doi:10.1007/978-3-030-64649-3_6
Management of Patients with Acute Hepatitis C
Cornberg, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-67762-6_10
Elimination of Hepatitis C Among HIV-positive Population in Asia: Old and New Challenges
Ohata, P. J., Lwin, H. M. S., Han, W. M., Khwairakpam, G., Tangkijvanich, P., Matthews, G. V., & Avihingsanon, A. (2021) · Future Virology · doi:10.2217/fvl-2021-0015
The elimination of disease and burden of disease
Popping, S. (2021) · EUR Research Repository (Erasmus University Rotterdam)
Arends, J. E., Leoni, M. C., & Salmon, D. (2019) · Springer eBooks · doi:10.1007/978-3-030-03757-4_11
Laguno, M., Martínez‐Rebollar, M., de la Mora, L., Pérez‐del‐Pulgar, S., & Mallolas, J. (2019) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2019.04.005
Remaining challenges for hepatitis C virus elimination in the era of direct-acting antiviral agents
Isfordink, C. J. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/1515
Laboratory Methods in Liver Pathology DiagnosisPreprint
Chesca, A. E., Medetova, A., Abdulina, G. A., Kouchebekov, B., Ahmetova, S., & Sandle, T. (2023) · Preprints.org · doi:10.20944/preprints202201.0226.v3
Laboratory Methods for Ill Liver DiagnosisPreprint
Chesca, A. E. (2024) · Preprints.org · doi:10.20944/preprints202312.0919.v2
Laboratory Analyse for Liver Diseases DiagnosisPreprint
Chesca, A. E. (2024) · Preprints.org · doi:10.20944/preprints202312.0919.v3
Arends, J. E., Leoni, M. C., & Ustianowski, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-49475-8_13
Considerations on Liver PathologyPreprint
Chesca, A. E. (2024) · Preprints.org · doi:10.20944/preprints202312.0919.v4
Laboratory Methods for Ill Liver AnalyzePreprint
Chesca, A. E. (2024) · Preprints.org · doi:10.20944/preprints202312.0919.v5
Harney, B. L., Sacks‐Davis, R., van Santen, D. K., Stewart, A. C., Matthews, G. V., Carson, J. M., Klein, M. B., Lacombe, K., Wittkop, L., Salmon, D., et al. (2024) · Liver International · doi:10.1111/liv.16203
Self-citationClassic Techniques for Pathological Liver AnalysePreprint
Chesca, A. E. (2025) · Preprints.org · doi:10.20944/preprints202312.0919.v6
Classic Structural Method for Pathological Liver AnalysePreprint
Chesca, A. E. (2025) · Preprints.org · doi:10.20944/preprints202312.0919.v7
Classic Method for Pathologically Liver AnalysePreprint
Chesca, A. E. (2025) · Preprints.org · doi:10.20944/preprints202312.0919.v8
Adachi, E., Kanno, Y., Koga, M., & Yotsuyanagi, H. (2025) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2025.102837
Recently acquired hepatitis C virus infection in people with HIV – what have we learned?
Benke, D., & Boesecke, C. (2025) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000001000
Self-citationCabezas, J., Ridruejo, E., Velasco, J. A. V.-R., Castro‐Narro, G., Cayon, L., Jiménez, C., Cheinquer, H., Contreras, F., Hernández, N., Perelló, C., et al. (2026) · Viruses · doi:10.3390/v18080861
Mansour, N., Elbarody, R. M. F., & Kamel, A. M. (2026) · Virology Journal · doi:10.1186/s12985-026-03307-x
Metadata
- Authors
- Ingiliz, P., Martin, T. C., Rodger, A., Stellbrink, H.-J., Mauss, S., Boesecke, C., Mandorfer, M., Bottero, J., Baumgarten, A., Bhagani, S., Lacombe, K., Nelson, M., & Rockstroh, J. K.
- Affiliations
- Chelsea and Westminster Hospital (GB)
- The Royal Free Hospital (GB)
- Infektionsmedizinisches Centrum Hamburg (DE)
- Center for HIV and Hepatogastroenterology (DE)
- University of Bonn (DE)
- Medical University of Vienna (AT)
- Assistance Publique – Hôpitaux de Paris (FR)
- Inserm (FR)
- Corresponding author
- Ingiliz, Patrick
- ORCID
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 66
- Issue
- 2
- Pages
- 282-287
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2520350813
- Cited by
- 173
- References
- 39
- Citations by year
- 2026: 2 · 2025: 10 · 2024: 11 · 2023: 10 · 2022: 19 · 2021: 14 · 2020: 19 · 2019: 35 · 2018: 30 · 2017: 18
- FWCI
- 20.96
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Journal of Hepatology (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion, cc-by-nc-nd)
- HAL (submittedVersion)
- Funders
- NEAT (LSHP-CT-2006-037570)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Health Sciences › Medicine › Gastroenterology › Helicobacter pylori-related gastroenterology studies
- Health Sciences › Medicine › Epidemiology › Cytomegalovirus and herpesvirus research
- Keywords
- HIV/HCV coinfection, men who have sex with men, spontaneous HCV clearance, ALT levels
- MeSH terms
- Adult, Antiviral Agents, Communicable Disease Control, Europe, Female, Hepatitis C, HIV Seropositivity, Humans, Male, Middle Aged, HIV Infections, Incidence, Hepacivirus, Homosexuality, Male, Coinfection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
